The combination of bisphosphonates and statins (probably with or without pemetrexed) may yield a superior therapy response in a subset of cancers such as TNBC and ovarian, pancreatic, and CNS cancer if such patients are stratified on the basis of the expression of FDPS, GGPS1, HMGCR, and GART in future clinical trials (Figure 6B). Here, HMGCR is linked to central nervous system cancer.